John Hartley is Professor of Cancer Studies in the UCL Cancer Institute and Scientific Lead of the UCL Experimental Cancer Medicine Centre. Prior to joining UCL he was a Fogarty Fellow at the National Cancer Institute, USA and an Alberta Heritage Research Fellow at the University of Alberta, Canada.
John has a B.Sc. in Biochemistry and a Ph.D. in Experimental Chemotherapy from the University of Manchester. He has over 350 publications in the fields of molecular and clinical pharmacology, DNA damage and repair, drug design and development, and cancer therapeutics.
He was a scientific founder of Spirogen Ltd, which was acquired by Astazeneca in 2013, and ADC Therapeutics which was spun out of Spirogen in 2012. He is a Fellow of both the Royal Societies of Biology and Chemistry, an Honorary Member of the Royal College of Radiologists and a Fellow of the Academy of Pharmaceutical Sciences. He has also been Chair of the Protocol Safety and Review Board of Cancer Research UK Centre for Drug Development since 2000.